Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Ben Hasty/MediaNews Group/Reading Eagle via Getty Images

The Biden administration will support a proposal to waive certain patent protections for coronavirus vaccines — a dramatic and controversial move designed to quickly bolster global supplies.

Why it matters: Proponents say this will help swiftly produce the vaccine doses that the developing world desperately needs. But the complex logistics of making and distributing the shots could limit the waiver’s impact, and critics say it sets a dangerous precedent.

The big picture: Developing nations and advocates on the left have been pushing the Biden administration for weeks to support a waiver of certain intellectual property rights to the vaccines, which the U.S., along with Europe and the pharmaceutical industry, had resisted until today.

  • A waiver would open the door for foreign manufacturers to make their own versions of coronavirus vaccines, using what would otherwise be considered Pfizer and Moderna's trade secrets.

The other side: Intellectual property rights are only one piece of the puzzle. Sourcing the ingredients for vaccines, standing up a complex manufacturing process, and distributing the finished doses all pose additional challenges.

  • Because of those factors, a patent waiver may not have much effect on supplies, and critics warn that the move could discourage drug companies from embarking on this kind of emergency research in the future.

What's next: Nothing's likely going to happen right away. Negotiations over the specifics of a waiver are ongoing, and will take time, U.S. Trade Representative Katherine Tai said in a statement.

Go deeper

How the messaging around FDA approval could boost COVID shots

Illustration: Brendan Lynch/Axios

Full FDA approval of the Pfizer vaccine can provide a big boost to vaccination efforts or a more modest one — depending on how it is handled when the decision comes down.

Between the lines: If FDA approval is left to be interpreted by the public through the countless channels of communication and misinformation people use to digest vaccine information, the effect of the decision will be much more modest or even muddled.

Aug 12, 2021 - Health

CDC head warns unauthorized boosters undermine safety monitoring

Rochelle Walensky. Photo: Greg Nash-Pool/Getty Images

Rochelle Walensky, director of the Centers for Disease Control and Prevention, warned Thursday that Americans getting unauthorized booster shots of the COVID-19 vaccine undermine the CDC's safety monitoring of recipients.

Why it matters: With booster shots a near inevitability, many Americans are eager to know when they will be able to get one. Some are now circumventing official CDC guidelines and getting a third shot.

Supreme Court lifts part of New York's eviction ban in win for landlords

Demonstrators in New York City at a rally calling for an extension of the state's eviction ban until 2022 and the cancellation of rent. Photo: Ed Jones/AFP via Getty Images

The Supreme Court lifted part of New York's COVID-related moratorium on home evictions in a divided ruling on Thursday evening.

Why it matters: The court sided with a group of landlords who argued that the ban violates their rights, but the ruling's immediate effect is unclear. The New York ban is separate from a federal eviction moratorium recently extended by the Centers for Disease Control and Prevention (CDC).

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!